pharmacoeconomic evaluation was performed using a direct cost comparison analysis, in which MAbs cost is compared (2011) (2012) (2013) (2014) to total drug cost per department, total in-patent drug cost, in-patent antibiotics cost and anti-HIV drug cost.
The cost saving of Central Cytostatic Drug Preparation Unit operation for the year 2014 was especially studied. The analysis was performed in Euros (€) and drug cost was based on average hospital prices in Greece (official price lists).
Results: Data analysis revealed that MAbs relative cost
showed an augmentative trend throughout the study period 
